Medtronic Secured FDA Approval for the Altaviva™ Device, Delivering a Simpler Experience in Treating Urge Urinary Incontinence
On September 19, 2025, Medtronic plc, a global leader in healthcare technology, announced that it had received U.S. Food and Drug Administration (FDA) approval for the Altaviva™ device. The minimally invasive implantable tibial neuromodulation (ITNM) therapy was inserted near the ankle and designed to treat urge urinary incontinence.
Bladder control problems affect an estimated 43 million, or one in six, U.S. adults. Of those, nearly 16 million people suffered from urge urinary incontinence, a common symptom of overactive bladder (...